Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
0.7990
-0.0120 (-1.48%)
At close: Jun 27, 2025, 4:00 PM
0.7850
-0.0140 (-1.75%)
After-hours: Jun 27, 2025, 7:51 PM EDT
Silexion Therapeutics Employees
As of December 31, 2024, Silexion Therapeutics had 14 total employees, including 11 full-time and 3 part-time employees.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,174,500
Market Cap
6.72M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SLXN News
- 5 weeks ago - PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment - GlobeNewsWire
- 5 weeks ago - Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer - GlobeNewsWire
- 6 weeks ago - Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities - GlobeNewsWire
- 3 months ago - Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - GlobeNewsWire
- 3 months ago - Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - GlobeNewsWire
- 3 months ago - Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment - Business Wire